Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019”

Claudia Sala, Laurent Roberto Chiarelli and Giovanna Riccardi

1. Introduction

*Mycobacterium tuberculosis*, the etiological agent of human tuberculosis (TB), represents a global challenge to human health since it is the main cause of death by an infectious disease worldwide. Estimations by the World Health Organization (WHO) reported that the tubercle bacillus latently infects approximately one fourth of the world’s population, and it is responsible for more than one million deaths every year [1]. Additional factors such as immunodeficiencies [2] and diabetes [3] increase the risk of developing active TB.

The currently available anti-TB therapy is composed of four antibiotics (rifampicin, isoniazid, pyrazinamide and ethambutol) that must be administered for at least 6 months to patients affected by drug-sensitive pulmonary TB [4]. However, the increasing number of multi- and extensively drug-resistant TB cases [5] requires the use of second- or even third-line anti-TB medications, which are characterized by frequent severe side-effects that reduce patients’ compliance [6].

Feeding the drug discovery pipeline with the identification of novel chemical entities and promoting the development of those candidate drugs that are presently in clinical trials are therefore of outmost importance in order to shorten anti-TB treatment.

In this Special Issue of Applied Sciences dedicated to “Tuberculosis Drug Discovery and Development”, we review the most recent achievements in drug and target identification and present an update on the clinical development of two candidate compounds (macozinone and delpazolid). An overview of technical advancements is included, together with a summary of the anti-TB vaccines which are either in the discovery or clinical phases.

2. The Present Special Issue on “Tuberculosis Drug Discovery and Development 2019”

This Special Issue of Applied Sciences dedicated to “Tuberculosis Drug Discovery and Development” starts with a review article by Bandodkar and colleagues [7] where several drug discovery approaches, which led to the identification of the TB drug candidates currently in the pipeline, are presented. In addition, the authors describe validated and promiscuous drug targets in the context of their experience at AstraZeneca R&D, Bangalore, India. In their article, Lienhardt and Raviglione discuss the ambitious aim of the WHO to reduce TB incidence by 90% by the year 2030 [8], whereas Iacobino and co-authors review the increasing global challenge represented by drug-resistant TB [9]. An interesting paper by Mazzarello closes the initial section by presenting a historical perspective focused on Carlo Forlanini, who invented pneumothorax for TB treatment in 1882, in the same year when Robert Koch identified *M. tuberculosis* as the causative agent of human TB [10].

The Special Issue then features a series of articles dedicated to the most relevant and frequently explored drug targets: the cell wall of *M. tuberculosis* is reviewed by Vilchèze [11], DprE1 and MmpL3...
are described by Degiacomi and co-workers [12], and the oxidative phosphorylation pathways are presented by Foo and colleagues [13]. In addition, Gries et al. report on the most recent advances in host-directed therapies and anti-virulence compounds, which could represent a helpful complement to current anti-TB approaches [14]. In the context of additional approaches to standard antibiotic treatment, an article by Visca et al. reviews the importance of post-TB treatment with the roles of surgery and rehabilitation [15]. Two candidate compounds which are in the advanced stages of development complete the section dedicated to novel medications: macozinone [16] and delpazolid [17].

Three papers describe state-of-the-art approaches to TB drug discovery. The first one by van Wijk and co-authors deals with quantitative pharmacology models including machine learning and artificial intelligence [18]; the second one by Bruch and colleagues discusses structure- and target-based approaches to TB drug design [19]; the last one explores the –omics technologies and how they have been exploited so far in TB drug discovery [20].

The Special Issue closes with an Editorial by Rappuoli who highlights the need for new drugs and vaccines to eradicate TB [21] and introduces the final article by Martin and colleagues [22] who wrote an update on the TB vaccine pipeline.

Overall, this Special Issue has gathered together most of the globally known TB professionals, including clinicians, academic staff as well as researchers from the private sector, and provides an extensive overview of the currently available tools and compounds that can help in the fight against TB.

3. Conclusions

The research work described in these sixteen reviews that constitute the Applied Sciences Special Issue provides an extremely useful example of the achieved results in the field of tuberculosis drug development. Moreover, readers can find information regarding the new approaches that are in progress to identify new antitubercular drugs, as well as novel drug targets.

We are extremely grateful to all of the authors for their excellent contribution to this Special Issue dedicated to Tuberculosis. We would also like to thank the reviewers who carefully evaluated the submitted manuscripts. Finally, special thanks to Ms. Marin Ma for her technical support.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. WHO. Global Tuberculosis Report 2019; WHO: Geneva, Switzerland, 2019.
2. du Bruyn, E.; Peton, N.; Esmail, H.; Howlett, P.J.; Coussens, A.K.; Wilkinson, R.J. Recent progress in understanding immune activation in the pathogenesis in HIV-tuberculosis co-infection. Curr. Opin. HIV AIDS 2018, 13, 455–461. [CrossRef] [PubMed]
3. Ferlita, S.; Yegiazyaryan, A.; Noori, N.; Lal, G.; Nguyen, T.; To, K.; Venketaraman, V. Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis. J. Clin. Med. 2019, 8, 2219. [CrossRef] [PubMed]
4. WHO. The End-TB Strategy; WHO: Geneva, Switzerland, 2014.
5. Mabhula, A.; Singh, V. Drug-resistance in Mycobacterium tuberculosis: Where we stand. MedChemComm 2019, 10, 1342–1360. [CrossRef] [PubMed]
6. Pontali, E.; Raviglione, M.C.; Migliori, G.B. Regimens to treat multidrug-resistant tuberculosis: Past, present and future perspectives. Eur. Respir. Rev. Off. J. Eur. Respir. Soc. 2019, 28. [CrossRef] [PubMed]
7. Bandodkar, B.; Shandil, R.; Bhat, J.; Balganesh, T. Two Decades of TB Drug Discovery Efforts—What Have We Learned? Appl. Sci. 2020, 10, 5704. [CrossRef]
8. Lienhardt, C.; Raviglione, M. TB Elimination Requires Discovery and Development of Transformational Agents. Appl. Sci. 2020, 10, 2605. [CrossRef]
9. Iacobino, A.; Fattorini, L.; Giannoni, F. Drug-Resistant Tuberculosis 2020: Where We Stand. Appl. Sci. 2020, 10, 2153. [CrossRef]
10. Mazzarello, P. A Physical Cure for Tuberculosis: Carlo Forlanini and the Invention of Therapeutic Pneumothorax. Appl. Sci. 2020, 10, 3138. [CrossRef]
11. Vilchée, C. Mycobacterial Cell Wall: A Source of Successful Targets for Old and New Drugs. Appl. Sci. 2020, 10, 2278. [CrossRef]
12. Degiacomi, G.; Belardinelli, J.; Pasca, M.; De Rossi, E.; Riccardi, G.; Chiarelli, L. Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3. Appl. Sci. 2020, 10, 623. [CrossRef]
13. Foo, C.; Pethe, K.; Lupien, A. Oxidative Phosphorylation—An Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis. Appl. Sci. 2020, 10, 2339. [CrossRef]
14. Gries, R.; Sala, C.; Rybniker, J. Host-Directed Therapies and Anti-Virulence Compounds to Address Anti-Microbial Resistant Tuberculosis Infection. Appl. Sci. 2020, 10, 2688. [CrossRef]
15. Visca, D.; Tiberi, S.; Centis, R.; D’Ambrosio, L.; Pontali, E.; Mariani, A.; Zampogna, E.; van den Boom, M.; Spanevello, A.; Migliori, G. Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. Appl. Sci. 2020, 10, 2734. [CrossRef]
16. Makarov, V.; Mikušová, K. Development of Macozinone for TB treatment: An Update. Appl. Sci. 2020, 10, 2269. [CrossRef]
17. Cho, Y.; Jang, J. Development of Delpazolid for the Treatment of Tuberculosis. Appl. Sci. 2020, 10, 2211. [CrossRef]
18. van Wijk, R.; Ayoun Alsoud, R.; Lennernäs, H.; Simonsson, U. Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations. Appl. Sci. 2020, 10, 2376. [CrossRef]
19. Bruch, E.; Petrella, S.; Bellinzoni, M. Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead. Appl. Sci. 2020, 10, 4248. [CrossRef]
20. Goff, A.; Cantillon, D.; Muraro Wildner, L.; Waddell, S. Multi-Omics Technologies Applied to Tuberculosis Drug Discovery. Appl. Sci. 2020, 10, 4629. [CrossRef]
21. Rappuoli, R. Drugs and Vaccines Will Be Necessary to Control Tuberculosis. Appl. Sci. 2020, 10, 4026. [CrossRef]
22. Martin, C.; Aguilo, N.; Marinova, D.; Gonzalo-Asensio, J. Update on TB Vaccine Pipeline. Appl. Sci. 2020, 10, 2632. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).